SEC Form 4 filed by Yeganeh Reuven
$PHGE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Issuer Name and Ticker or Trading Symbol
BiomX Inc. [ PHGE ] | 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| |||||||||||||||||||||||||
| 2a. Foreign Trading Symbol
| |||||||||||||||||||||||||||
| 3. Date of Earliest Transaction
(Month/Day/Year) 03/16/2026 | 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed
(Month/Day/Year) |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock, $0.0001 par value per share | 03/16/2026 | C(1) | 450,000 | A | $2(1) | 450,000 | I | Pyu Pyu Capital LLC(2) | ||
| Common Stock, $0.0001 par value per share | 03/16/2026 | S(3) | 450,000 | D | $5(3) | 0 | I | Pyu Pyu Capital LLC(2) | ||
| Common Stock, $0.0001 par value per share | 03/17/2026 | C(1) | 530,000 | A | $2(1) | 530,000 | I | Pyu Pyu Capital LLC(2) | ||
| Common Stock, $0.0001 par value per share | 03/17/2026 | S(3) | 530,000 | D | $5(3) | 0 | I | Pyu Pyu Capital LLC(2) | ||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series Y Convertible Preferred Stock | $2(1) | 03/16/2026 | C(1) | 900 | 01/13/2026 | 01/13/2027 | Common Stock | 450,000 | $0(1) | 1,060 | I | Pyu Pyu Capital LLC(2) | |||
| Series Y Convertible Preferred Stock | $2(1) | 03/17/2026 | C(1) | 1,060 | 01/13/2026 | 01/13/2027 | Common Stock | 530,000 | $0(1) | 0 | I | Pyu Pyu Capital LLC(2) | |||
| Common Stock Purchase Warrants | $1 | 03/16/2026 | S(4) | 1,300,000 | 01/13/2026 | 01/13/2031 | Common Stock | 1,300,000 | $5 | 2,000,000 | I | Pyu Pyu Capital LLC(2) | |||
| Common Stock Purchase Warrants | $1 | 03/16/2026 | S(4) | 2,000,000 | 01/13/2026 | 01/13/2031 | Common Stock | 300,000 | $5.24 | 1,700,000 | I | Pyu Pyu Capital LLC(2) | |||
| Common Stock Purchase Warrants | $1 | 03/16/2026 | S(4) | 1,700,000 | 01/13/2026 | 01/13/2031 | Common Stock | 1,700,000 | $4.76 | 0 | I | Pyu Pyu Capital LLC(2) | |||
| Explanation of Responses: |
| 1. Represents shares of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer received upon conversion of the Issuer's Series Y Convertible Preferred Stock, par value $0.0001 per share, held by the Reporting Person at a conversion price equal to $2.00 per share. |
| 2. The reported securities are directly owned by Pyu Pyu Capital, LLC ("Pyu Pyu") and may be deemed to be beneficially owned by the Reporting Person as sole member of Pyu Pyu. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| 3. The shares of Common Stock were sold in private transactions at a price of $5.00 per share. |
| 4. The warrants were sold in private transactions at the specified price per warrant share. |
| /s/ Reuven Yeganeh | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 4: SEC 1474 (03-26) | ||